Por: The Boston Globe Business July 17, 2023
The race to bring Alzheimer’s drugs to patients heated up Monday when Eli Lilly released promising new clinical findings for a treatment that with one developed by Cambridge-based Biogen and its Japanese business partner that won full US approval this month.Lilly, the pharma giant based in Indianapolis, said its experimental drug, called donanemab, slowed cognitive and functional decline by 35 percent in a late-stage clinical trial of... + full article
The Boston Globe USA Business July 25, 2023
Biogen said Tuesday that it plans to cut about 1,000 jobs, roughly 11 percent of its global workforce, to lower costs as the Cambridge-based biotech begins to roll out the new Alzheimer’s drug it co-developed and prepares for possible approval of another drug, for depression,... + más
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes
FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says | Fox Business
Orlando Sentinel USA Sports March 25, 2023
Orangewood Christian 11, The Master’s Academy 1 Buzz: Austin Waring threw 5 innings of 1-run ball (0 earned runs) while allowing 4 hits and striking out 8 for Orangewood Christian. He lowered his season ERA to 0.78. Aiden McKee went 3-for-3 with a double, a walk, an RBI and a... + más
NFL Playoff Scenarios | ABC News
Le Krewe du Roi celebrates the state at 58th annual Mardi Gras Ball | The Advocate
New York Daily News USA Nation March 01, 2023
Drugmaker Eli Lilly said Wednesday it would slash prices on several insulin formulations by 70% and expand eligibility for a monthly price cap. The move came as federal pressure mounted on the pharmaceutical giant and was hailed as a major win by advocates for people with... + más
Eli Lilly caps out-of-pocket costs for insulin effective immediately | Fox Business
Drugmaker Eli Lilly caps the cost of insulin at $35 a month, bringing relief for millions | NBC News
Fox Business USA Business December 30, 2022
BioVie president and CEO Cuong Do discusses the positive results of its Parkinson's and Alzheimer's phase 2 trials and explains how its NE3107 drug could reverse the biological clock on 'Varney & Co.' An 18-month-long investigation conducted by the House... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | WPLG Local 10
Probe: Alzheimer's drug approval 'rife with irregularities' | 10 WBNS
Forbes USA Business December 09, 2022
an elderly woman exercising to combat Alzheimer's disease in a care center for elderly, Galicia, ... [+] 27th November 2007. (Photo by Xurxo Lobato/Cover/Getty Images)Cover/Getty Images What should people living with dementia and their families take away from the the... + más
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners | MarketWatch
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
Fox Business USA Business September 28, 2022
Dr. Stephen O'Brien, chief medical officer of Mediflix, shares how his streaming platform is trailblazing access to medical information for everyone. Shares of Biogen surged Wednesday's following news that its drug lecanemab showed promising signs of potentially... + más
Biogen shares rally as Alzheimer's drug results show promise | CBS News
Alzheimer's drug shows promise in early results of study | WPLG Local 10
About iurex | Privacy Policy | Disclaimer |